Gilead Sciences Inc., a manufacturer of the antiviral remdesivir drug used to treat Corona virus patients, revealed that the drug would sell for US $ 2,340 or around Rp 33 million for patients treated for 5 days.
The company announced a pricing plan for COVID-19 drug costs in July. Gilead Sciences Inc. has also previously donated several doses to the US government for distribution since remdesivir received an authorization for emergency use in May.
Quoted from CNN International, the company said it would sell remdesivir for US $ 390 or around Rp5.6 million per vial to ‘developed countries’ throughout the world and prices for private companies would range around US $ 520 or around Rp4.4 million per vial.
Most COVID-19 patients on average undergo five days of hospital treatment and receive about 6 doses of remdesivir. In the United States alone, Gilead will set a lower price for government programs so that the cost charged to the US government becomes US $ 2,340 or Rp 33 million per patient who is hospitalized for five days.
Specifically for 10 days treatment with a dose of 11 vial remdesivir, the company will cost the government US $ 4,290 or Rp. 61 million per patient and US $ 5,720 or Rp. 82 million for US patients with private insurance.
“At this level we have set the price of remdesivir and with government programs, together with Gilead assistance as needed, we believe all patients will have access,” said Gilead CEO Daniel O’Day in an open letter.
Watch Video “Dr. Reisa Appeals to People Not to Use Antibiotics During Corona Pandemic“
[Gambas:Video 20detik]
(kna / up)
– .
